Ratio Therapeutics

Ratio is pleased to welcome John Marquis, PhD, as our new Vice President, Discovery Program Integration! With experience in drug discovery and development at Merck and Molecular Insight Pharmaceuticals, Dr. Marquis brings a proven track record of driving the direction and progress of scientific teams to define and develop therapeutic candidates. Welcome aboard the Ratio team!

Thank you, Michael Gibney for featuring Ratio in this PharmaVoice article about the recent "radio-renaissance". Our CEO Jack Hoppin discusses why pharma has taken a renewed interest in #radiopharmaceuticals and why smaller companies are at the center of innovation for this field. Full article: https://lnkd.in/g78yDwjv

Next week, Dr. Matthias Friebe, Chief Technology Officer, will be delivering a seminar at the upcoming 2nd Annual Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit, taking place September 24-26, 2024 in Boston, MA. Presentation Details: Title: Overcoming Manufacturing Bottlenecks & Maintaining Quality in Radiopharmaceutical Production Date: Wednesday, September 25, 2024 Time: 2:45 PM ET Dr. Friebe’s presentation will examine the shortage of manufacturing facilities, identify quality control challenges, and explore effective approaches to streamline production. Register today: https://lnkd.in/gsrXiJiU #radiopharmaceuticals #conference #TRP

Positive momentum in the field of #radiopharmaceuticals continues with Novartis’ $200 million investment in a new manufacturing facility in Carlsbad, CA as well as the expansion of an existing production site in Indianapolis. Novartis expects to employ up to 90 people to support this development. ? This investment underscores a growing belief within the industry in the potential of radiopharmaceuticals to revolutionize #cancer treatment. Every dollar invested into manufacturing facilities and training programs puts us a step closer to the most important goal: bringing therapies to patients in need. A rising tide lifts all boats! ? Learn more in this article from STAT: https://lnkd.in/eNzg3pWN ? #PrecisionMedicine #news #manufacturing

Ratio team members Dr. Jacob Hesterman, CDO, and Dr. Caitlin McCutcheon, Senior Research Associate, will be leading a webinar in collaboration with Scintica on September 18, 2024, at 12 PM ET. The webinar will cover the calibration and characterization of the Gamma Eye system for Ac-225 imaging and in vivo imaging results of [225AC]DOTATATE in mice. Learn more and register here: https://lnkd.in/eGVC5dsC #radiopharmaceuticals #molecularimaging #nuclearmedicine #drugdiscovery

Dr. Shawn Hillier, Ratio’s Head of Preclinical Development, will be presenting at the Translational Oncology Symposium on September 17, 2024. Presentation Details: Title: It's More Than Affinity: The Art of Binding Radiopharmaceuticals with Precision and Passion Date: September 17, 2024 Time: 11:30 AM – 12 PM ET Location: Cambridge Innovation Center Register here: https://lnkd.in/g8s78YPq #Radiopharmaceuticals #Cancer #TranslationalOncology

A key component of Ratio’s proprietary Trillium? platform is Macropa?, a best-in-class chelator for actinium-225 alpha radiotherapy. ? Macropa? rapidly complexes Ac-225 at room temperature. This unique chelator displays exceptional selectivity for Ac-225, producing highly pure and stable drug products. Macropa? can be used with a wide variety of compounds, from small molecules to peptides and even large polypeptides, such as antibodies. ? Learn more about Ratio’s technologies or reach out to Ratio’s corporate development team at [email protected] to discuss partnership and licensing opportunities. https://ratiotx.com/

Interested to see how it is possible to efficiently image Ac-225 in mice? On September 18th, at 06:00 PM (CET), our US collaborators, Dr. Jacob Hesterman and Dr. Caitlin McCutcheon from Ratio Therapeutics, will describe their experience on working with BIOEMTECH Gamma Eye for imaging Actinium-225 (225Ac). In this webinar they will dive into: - The calibration and characterization of the Gamma Eye system for 225Ac imaging. - In vivo imaging results of [225Ac]DOTATATE in mice, with qualitative and quantitative analysis at multiple time points. - Comparisons with [177Lu]DOTATATE imaging to highlight the benefits and limitations of 225Ac. You can contact our Scintica, our N. America distributors and register here: https://lnkd.in/dhDXejSc #preclinicalimaging, #molecularimaging, #radiopharmaceuticals, #nuclearmedicine, #theragnostics, #drugdiscovery

This Prostate Cancer Awareness Month, we encourage men to take charge of their health through regular screenings, a balanced diet, and active lifestyles—key steps in preventing prostate cancer. Early detection is vital, and making informed lifestyle choices can significantly reduce the risk. At Ratio, we're proud to support this mission by developing best-in-class #radiopharmaceuticals to both diagnose and treat prostate cancer more effectively. Your health is in your hands — let's work together to prevent prostate cancer. Learn more: https://bit.ly/3MiHtwy #Cancer #ProstateCancerAwarenessMonth #ProstateCancer

Exciting developments in the field of #radiopharmaceutical imaging. Telix Pharmaceuticals has submitted a New Drug Application (NDA) for TLX101-CDx, an investigational PET imaging agent designed to help characterize gliomas, the most common primary brain tumors. This is a significant step forward for patients, as currently, no FDA-approved targeted PET agents are available for imaging brain #cancer. At Ratio, we are encouraged by this news, as we believe that radiopharmaceuticals have the potential to provide patients and clinicians with the information needed to better understand diagnosis and treatment decisions. Read more about this milestone at Targeted Oncology: https://bit.ly/4e3LVej